Altoida
Altoida develops an AI- and augmented reality-powered Digital NeuroMarker Platform that delivers a 10-minute self-administered cognitive assessment for early detection of Mild Cognitive Impairment and Alzheimer's disease, serving pharmaceutical companies, healthcare providers, and research institutions.
- Company typePrivate
- Founded2005
- HeadquartersWashington, United States
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What Altoida does
Altoida, Inc. is a Washington, DC-based, privately held digital diagnostics company developing an AI- and augmented reality-powered Digital NeuroMarker Platform for early detection of Mild Cognitive Impairment (MCI) and Alzheimer's disease. The core offering is a 10-minute, self-administered tablet-based assessment that captures multimodal sensor data (accelerometer, gyroscope, touchscreen, AR interactions, speech) as users complete neuroscience-driven tasks simulating instrumental activities of daily living. This data feeds proprietary machine learning models called Digital Neuro Signatures (DNS) that produce a 0-100 score distinguishing cognitively normal from cognitively impaired individuals, with published evidence of 94% accuracy in predicting Alzheimer's disease conversion within 12 months and validation in Nature Digital Medicine.
The platform combines augmented reality, sensor fusion, and explainable AI, has been validated across more than 42,000 tests and 20,000+ participants over 20+ years of research, and received FDA Breakthrough Device Designation in 2021 for its first predictive ML algorithm. A DNS-MCI algorithm patent is filed-pending, and the platform is positioned for extension into Parkinson's, TBI, and depression indications. SOC 2 Type II and ISO 27001 certifications support enterprise readiness.
Altoida pursues a B2B enterprise go-to-market targeting pharmaceutical companies for clinical trial enrichment and patient selection (anchored by Eisai's 5-year multi-center Alzheimer's study), cognitive care specialty providers such as Mindspan for care pathway integration, and academic research institutions. The company is pre-commercial: the platform is investigational only, not FDA cleared, and not available for sale. Anticipated revenue streams upon clearance include platform licensing and royalties to pharma, subscription-based clinical diagnostics services to healthcare systems, and research partnership income. Approximately $24.7M has been raised across nine funding rounds through Series A ($20.3M total, 2022), led by M Ventures (Merck KGaA's strategic CVC arm) and Whitecap Venture Partners, with additional backing from Hikma Ventures, Eisai Innovation, and the Alzheimer's Drug Discovery Foundation.
Altoida firmographics
Firmographics- Name
- Altoida
- Legal name
- Altoida, Inc.
- Website
- https://altoida.com
- Company type
- Private
- Founded year
- 2005
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Altoida develops an AI- and augmented reality-powered Digital NeuroMarker Platform that delivers a 10-minute self-administered cognitive assessment for early detection of Mild Cognitive Impairment and Alzheimer's disease, serving pharmaceutical companies, healthcare providers, and research institutions.
- Ownership category
- akta.pro rank
Altoida industry classification
Industry- Product category
- Digital Neurological Diagnostics
- NAICS
- Software Publishers (5132)
- SIC
- Services-Prepackaged Software (7372)
- akta.pro primary industry
- SaMD – Digital Biomarkers & Algorithmic Endpoints (HLACANAF)
- akta.pro secondary industries
- Behavioral Health & Neurocognitive Therapeutics (Digital) (HLACANAI), Neurology RPM (epilepsy, Parkinson’s, MS monitoring) (HLALAFAJ)
Keywords
Where Altoida is headquartered
LocationHeadquarters
- HQ city
- Washington
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Altoida business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure
Revenue model
- Platform Licensing to Pharma: Licensing the investigational platform to pharmaceutical companies for incorporation into CNS clinical trials, supporting patient selection, treatment monitoring, and disease progression research.
- Clinical Diagnostics Services: Providing cognitive assessment services to healthcare systems and clinical care settings once FDA cleared. Platform intended for clinical use in primary care and specialty neurology settings.
- Research Partnerships: Research partnerships with pharmaceutical companies like Eisai for collaborative studies and clinical exploration, including the 5-year multi-center Alzheimer's study.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Investigational use only - not commercially available |
Go-to-market motion2 records
Distribution channels3 records
Marketing channels5 records
Altoida product offering
Product offeringCore offering
Altoida develops and provides the Digital NeuroMarker Platform, an AI- and augmented reality-powered digital cognitive assessment that delivers a 10-minute, self-administered test on a smart tablet to capture hundreds of multimodal digital biomarkers (motor, speech, AR, and cognitive data). The platform produces a Digital Neuro Signature (DNS) score (0-100) to detect Mild Cognitive Impairment (MCI) and predict conversion to Alzheimer's disease. The product is currently offered for investigational use and clinical trial enrichment to pharmaceutical and biotech partners, with planned clinical adoption in healthcare systems upon FDA clearance.
Product overview
Altoida offers a unified Digital NeuroMarker Platform centered around its AI and AR-powered cognitive assessment technology. The core offering consists of a 10-minute, tablet-based Digital Cognitive Assessment that uses augmented reality to simulate daily living activities while capturing multimodal sensor data. This data feeds into proprietary machine learning models called Digital Neuro Signatures (DNS) that generate scores for detecting Mild Cognitive Impairment and Alzheimer's disease. The platform is designed for both in-clinic and remote administration, targeting healthcare providers, pharmaceutical companies for clinical trials, and research institutions.
Differentiator
Problem solved
Functional benefit
Brands
- NeuroMarker Platform: AI and augmented reality-powered digital platform designed to rapidly detect early cognitive decline and assess brain health through multimodal digital biomarkers.
- Digital NeuroMarker Platform
- Digital Neuro Signature (DNS)
Products and services
- Digital NeuroMarker Platform Multi-modal AI and AR-powered platform delivering a 10-minute, self-administered cognitive assessment that captures hundreds of digital biomarkers across motor, speech, AR, and cognitive domains to detect Mild Cognitive Impairment (MCI) and Alzheimer's disease earlier than traditional methods. Designed for healthcare providers, pharmaceutical clinical trials, and research institutions.
- Digital Cognitive Assessment A 10-minute self-administered assessment using a smart tablet that leverages augmented reality to simulate activities of daily living while capturing motion, speech, and touch data for objective cognitive evaluation. Currently investigational use only.
- Digital Neuro Signature (DNS) Machine learning model trained on multimodal sensor data that generates an ordinal DNS score (0-100) to distinguish cognitively normal from cognitively impaired participants. Filed as a pending patent (inventions/methods).
Quantifiable outcome
- 94% accuracy in predicting Alzheimer's disease within one year
- +4 more outcomes
Companies that use Altoida
Customer profileNamed customers5 records
Segments4 records
Ideal customer profiles3 records
Altoida technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability5 records
Feature5 records
Altoida partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered flagship, core and supporting.
- MindspanflagshipResearch collaboration to evaluate integration of Altoida's AI/AR-powered digital NeuroMarker platform into Mindspan's personalized cognitive care delivery model. Pilot study enrolling up to 100 adults to assess clinical, operational, and economic impacts.
- RADAR-AD ConsortiumcoreEuropean project funded by Innovative Medicines Initiative (IMI) evaluating remote monitoring technologies including Altoida's AR digital cognitive assessment for early identification of Alzheimer's Disease. Published in Nature Digital Medicine.
- Hospital Clinic Barcelona & Barcelona-Beta Brain Research CentersupportingDual-center clinical study sites for 188-participant cross-sectional study validating Altoida's digital cognitive assessment against standard neuropsychological tests.
- Ionian UniversitycoreAcademic collaboration for the 5-year multi-center Alzheimer's study conducted with Eisai, advancing research into the Alzheimer's Disease continuum.
- EisaiflagshipResearch partnership focused on developing predictive diagnostics for neurodegenerative diseases like Alzheimer's. Includes financing and collaboration on the 5-year multi-center Alzheimer's study launched in October 2023 with Ionian University.
Scale indicators5 records
Recent moves6 records
Expansion highlights5 records
Altoida competitors and assessment
Company assessmentEmerging players
- C2N Diagnostics: Commercial-stage diagnostics company offering PrecivityAD blood-based Alzheimer's biomarker tests. Comparable in targeting early Alzheimer's detection for clinical decision-making and pharma trial enrichment, though using a different modality (blood biomarkers vs. Altoida's digital biomarkers).
- BrainCheck: Digital cognitive assessment platform delivering rapid, tablet-based cognitive testing for clinicians. Comparable in targeting the same primary-care and specialty workflow pain points Altoida addresses, though focused on broader cognitive domains rather than AR-based neurocognitive biomarkers.
- Neurotrack: Digital health company developing cognitive assessment and Alzheimer's risk tools for consumers and clinical use. Comparable in targeting early detection of cognitive decline through digital means, though with a stronger consumer-facing orientation than Altoida's clinical/research focus.
- Linus Health: Boston-based digital health company offering AI-powered cognitive assessment (including DCTclock) for early detection of cognitive impairment. Directly comparable in targeting MCI/Alzheimer's early detection with digital tools, though with different technology stack (pen-and-digitizer vs. Altoida's AR-based approach).
Broad incumbents
- Quanterix: Public company offering ultra-sensitive biomarker measurement platforms (Simoa) used in Alzheimer's and neurodegenerative disease research and diagnostics. Comparable as a neurology biomarker platform serving pharma and clinical research customers, though operating in the blood-based biomarker modality rather than digital.
- Biogen: Large biotech with leading Alzheimer's franchise (Aduhelm/Leqembi partnership). Comparable as a major incumbent shaping Alzheimer's diagnostic and therapeutic standards, and as a potential enterprise customer or competitor for diagnostic partnerships in pharma clinical trials.
- Eli Lilly: Global pharma with the Kisunla Alzheimer's therapy and active R&D into Alzheimer's diagnostics (including blood-based biomarker programs). Comparable as a broad incumbent defining the Alzheimer's treatment and diagnostic landscape in which Altoida's platform competes for pharma trial enrichment partnerships.
Direct peers
- Cambridge Cognition: Public UK-based digital cognitive assessment company with the CANTAB battery used in research and clinical trials. Directly comparable to Altoida in addressing pharmaceutical CNS trial enrichment and clinical cognitive assessment, with overlapping customer base and regulatory positioning.
- Cogstate: Public digital cognitive assessment company providing computerized tests for clinical trials and healthcare. Cogstate is the closest direct peer to Altoida, sharing the same digital cognitive assessment value proposition for pharma trial enrichment and clinical use, with an established commercial footprint Altoida is still building toward.
Others
- Eisai: Global pharmaceutical company that is both an Altoida investor and research partner, with major Alzheimer's franchise (Leqembi). Relevant as the pharma incumbent defining the Alzheimer's treatment landscape in which Altoida's diagnostic platform operates, and as a strategic capital and commercialization partner.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Altoida social profiles
Digital presenceAltoida compliance and trust
Trust signalCompliance2 records
Altoida financial estimates
Financial estimateRevenue estimate
Valuation estimate
Altoida leadership team
Management profileNumber of profiles
Profiles9 records
Altoida funding detail
Funding detailFunding overview
Funding rounds9 records
Investors13 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Altoida M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Altoida
What does Altoida do?
Altoida develops and provides the Digital NeuroMarker Platform, an AI- and augmented reality-powered digital cognitive assessment that delivers a 10-minute, self-administered test on a smart tablet to capture hundreds of multimodal digital biomarkers (motor, speech, AR, and cognitive data). The platform produces a Digital Neuro Signature (DNS) score (0-100) to detect Mild Cognitive Impairment (MCI) and predict conversion to Alzheimer's disease. The product is currently offered for investigational use and clinical trial enrichment to pharmaceutical and biotech partners, with planned clinical adoption in healthcare systems upon FDA clearance.
Is Altoida a public or private company?
Altoida is a private company. It is classified as venture growth investor backed and is currently operating.
When was Altoida founded?
Altoida was founded in 2005. It employs 11 to 50 people.
Where is Altoida based?
Altoida is headquartered in Washington, United States, in the North America region.
How does Altoida make money?
Three revenue lines are on record. Platform Licensing to Pharma is the primary driver. The others are clinical Diagnostics Services and research Partnerships.
Who are Altoida's main competitors?
Emerging players on record are C2N Diagnostics, BrainCheck, Neurotrack and Linus Health. Broad incumbents are Quanterix, Biogen and Eli Lilly. Direct peers are Cambridge Cognition and Cogstate. Eisai is listed as an others.
Does Altoida have an API?
No public API is recorded for Altoida.
What industry is Altoida in?
Altoida's product category is Digital Neurological Diagnostics. Its primary akta.pro industry code is HLACANAF, SaMD – Digital Biomarkers & Algorithmic Endpoints, with a secondary code of HLACANAI, Behavioral Health & Neurocognitive Therapeutics (Digital). Its NAICS code is 5132 and its SIC code is 7372.